María José Juan-Fita

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

MicroRNA signatures in hereditary breast cancer

Rosa Murria Estal, Sarai Palanca Suela, Inmaculada de Juan Jiménez et al. · Breast Cancer Research and Treatment · 2013 · 45 citations

Life Sciences, Molecular Biology, Oncology +14

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

Begoña Pérez‐Valderrama, Jóse Ángel Arranz Arija, Ángel Rodríguez Sánchez et al. · Annals of Oncology · 2015 · 37 citations · Full text

Medicine, Oncology, Pharmacology +15

Whole exome sequencing identifies <i>PLEC</i>, <i>EXO5</i> and <i>DNAH7</i> as novel susceptibility genes in testicular cancer

Beatriz Paumard‐Hernández, Oriol Calvete, Lucía Inglada‐Pérez et al. · International Journal of Cancer · 2018 · 35 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

Miguel Ángel Climent, Begoña Pérez‐Valderrama, Begoña Mellado et al. · European Journal of Cancer · 2017 · 21 citations

Medicine, Oncology, Pharmacology +12